The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform

Rmc Herings - One of the best experts on this subject based on the ideXlab platform.

  • treatment patterns and health care costs of mebeverine treated ibs patients a case control study
    Pharmacoepidemiology and Drug Safety, 2004
    Co-Authors: Wim Goettsch, G. Van Den Boom, Nancy S Breekveldtpostma, Andre J P M Smout, Rmc Herings
    Abstract:

    Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Netherlands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable. Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls. Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy for IBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and incidence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Concomitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy for constipation-IBS) and their controls. Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users used laxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratio for hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxative use (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were €94 [95%CI €79–€109] and for hospital admissions €120 [€74–€166] per mebeverine user. In mebeverine users with Concomitant laxative use these costs were €136 and €251 respectively. Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls. Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. The total mean excess cost per patient per year is €482. Copyright © 2004 John Wiley & Sons, Ltd.

  • PGS10: TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS:A CASE-CONTROL STUDY
    Value in Health, 2003
    Co-Authors: Wim Goettsch, G. Van Den Boom, N Breekveldt, Andre J P M Smout, Rmc Herings
    Abstract:

    SUMMARY Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Nether-lands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable.Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls.Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy forIBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and inci-dence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Con-comitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy forconstipation-IBS) and their controls.Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users usedlaxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratiofor hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxativeuse (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were s94 [95%CI s79–s109] andfor hospital admissions s120 [s74–s166] per mebeverine user. In mebeverine users with Concomitant laxative use thesecosts were s136 and s251 respectively.Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls.Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. Thetotal mean excess cost per patient per year is s482. Copyright # 2004 John Wiley & Sons, Ltd.key words—mebeverine; irritable bowel syndrome; matched case control study; incidence; laxatives; hospital morbidity;co-medication; health care costs

Isabelle Morel - One of the best experts on this subject based on the ideXlab platform.

  • death related to consumption of rauvolfia sp powder mislabeled as tabernanthe iboga
    Forensic Science International, 2016
    Co-Authors: Thomas Gicquel, Chloe Hugbart, Francoise Lohezicle Devehat, Sylvie Lepage, Alain Baert, Renaud Bouvet, Isabelle Morel
    Abstract:

    Powdered roots of iboga (Tabernanthe iboga) contain ibogaine, an alkaloid that has been used to treat addictions. We report the case of a 30-year-old woman who died after ingesting a powder labeled as Tabernanthe iboga she had bought online. Analysis of the powder revealed the absence of ibogaine but the presence of toxic alkaloids (ajmaline, yohimbine and reserpine) found in Rauvolfia sp. plant species. An original and specific LC–MS/MS method developed to quantify ajmaline, yohimbine and reserpine showed respective concentrations of 109.1 ng/mL, 98.2 ng/mL and 30.8 ng/mL in blood, and 1528.2 ng/mL, 914.2 ng/mL and 561.2 ng/mL in bile. Moreover, systematic toxicological analyses of biological samples showed the presence of oxazepam at therapeutic concentration and cannabinoids. Death could be attributed to ingestion of a substantial quantity of crushed roots of Rauvolfia in association with Concomitant Drug withdrawal.

Wim Goettsch - One of the best experts on this subject based on the ideXlab platform.

  • treatment patterns and health care costs of mebeverine treated ibs patients a case control study
    Pharmacoepidemiology and Drug Safety, 2004
    Co-Authors: Wim Goettsch, G. Van Den Boom, Nancy S Breekveldtpostma, Andre J P M Smout, Rmc Herings
    Abstract:

    Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Netherlands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable. Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls. Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy for IBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and incidence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Concomitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy for constipation-IBS) and their controls. Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users used laxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratio for hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxative use (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were €94 [95%CI €79–€109] and for hospital admissions €120 [€74–€166] per mebeverine user. In mebeverine users with Concomitant laxative use these costs were €136 and €251 respectively. Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls. Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. The total mean excess cost per patient per year is €482. Copyright © 2004 John Wiley & Sons, Ltd.

  • PGS10: TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS:A CASE-CONTROL STUDY
    Value in Health, 2003
    Co-Authors: Wim Goettsch, G. Van Den Boom, N Breekveldt, Andre J P M Smout, Rmc Herings
    Abstract:

    SUMMARY Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Nether-lands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable.Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls.Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy forIBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and inci-dence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Con-comitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy forconstipation-IBS) and their controls.Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users usedlaxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratiofor hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxativeuse (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were s94 [95%CI s79–s109] andfor hospital admissions s120 [s74–s166] per mebeverine user. In mebeverine users with Concomitant laxative use thesecosts were s136 and s251 respectively.Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls.Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. Thetotal mean excess cost per patient per year is s482. Copyright # 2004 John Wiley & Sons, Ltd.key words—mebeverine; irritable bowel syndrome; matched case control study; incidence; laxatives; hospital morbidity;co-medication; health care costs

G. Van Den Boom - One of the best experts on this subject based on the ideXlab platform.

  • treatment patterns and health care costs of mebeverine treated ibs patients a case control study
    Pharmacoepidemiology and Drug Safety, 2004
    Co-Authors: Wim Goettsch, G. Van Den Boom, Nancy S Breekveldtpostma, Andre J P M Smout, Rmc Herings
    Abstract:

    Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Netherlands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable. Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls. Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy for IBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and incidence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Concomitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy for constipation-IBS) and their controls. Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users used laxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratio for hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxative use (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were €94 [95%CI €79–€109] and for hospital admissions €120 [€74–€166] per mebeverine user. In mebeverine users with Concomitant laxative use these costs were €136 and €251 respectively. Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls. Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. The total mean excess cost per patient per year is €482. Copyright © 2004 John Wiley & Sons, Ltd.

  • PGS10: TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS:A CASE-CONTROL STUDY
    Value in Health, 2003
    Co-Authors: Wim Goettsch, G. Van Den Boom, N Breekveldt, Andre J P M Smout, Rmc Herings
    Abstract:

    SUMMARY Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Nether-lands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable.Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls.Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy forIBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and inci-dence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Con-comitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy forconstipation-IBS) and their controls.Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users usedlaxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratiofor hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxativeuse (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were s94 [95%CI s79–s109] andfor hospital admissions s120 [s74–s166] per mebeverine user. In mebeverine users with Concomitant laxative use thesecosts were s136 and s251 respectively.Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls.Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. Thetotal mean excess cost per patient per year is s482. Copyright # 2004 John Wiley & Sons, Ltd.key words—mebeverine; irritable bowel syndrome; matched case control study; incidence; laxatives; hospital morbidity;co-medication; health care costs

Andre J P M Smout - One of the best experts on this subject based on the ideXlab platform.

  • treatment patterns and health care costs of mebeverine treated ibs patients a case control study
    Pharmacoepidemiology and Drug Safety, 2004
    Co-Authors: Wim Goettsch, G. Van Den Boom, Nancy S Breekveldtpostma, Andre J P M Smout, Rmc Herings
    Abstract:

    Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Netherlands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable. Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls. Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy for IBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and incidence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Concomitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy for constipation-IBS) and their controls. Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users used laxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratio for hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxative use (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were €94 [95%CI €79–€109] and for hospital admissions €120 [€74–€166] per mebeverine user. In mebeverine users with Concomitant laxative use these costs were €136 and €251 respectively. Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls. Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. The total mean excess cost per patient per year is €482. Copyright © 2004 John Wiley & Sons, Ltd.

  • PGS10: TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS:A CASE-CONTROL STUDY
    Value in Health, 2003
    Co-Authors: Wim Goettsch, G. Van Den Boom, N Breekveldt, Andre J P M Smout, Rmc Herings
    Abstract:

    SUMMARY Background Irritable bowel syndrome (IBS) is a functional disorder affecting the quality of life of patients. In the Nether-lands, mebeverine is currently the only medical treatment registered for IBS, although its efficacy is considered disputable.Objective To assess treatment patterns and associated health care cost in mebeverine users relative to matched controls.Methods A matched case-control study was performed using pharmacy data. Cases were mebeverine users as proxy forIBS patients. Controls were non-mebeverine users and matched to cases by age, gender and pharmacy. Prevalence and inci-dence of mebeverine use, Concomitant Drug use and hospitalizations were assessed in 3431 cases and 3431 controls. Con-comitant Drug use and hospitalizations was also assessed in a subgroup of 1222 users of mebeverine and laxatives (proxy forconstipation-IBS) and their controls.Results Twelve per 1000 residents were ever-dispensed mebeverine in 1998. One-third of these mebeverine users usedlaxatives Concomitantly. Concomitant Drug use and hospitalizations were increased in mebeverine users. The odds ratiofor hospitalizations for gastrointestinal reasons was increased predominantly in mebeverine users with Concomitant laxativeuse (OR:8.7; 95%CI [4.3–17.3]). Excess yearly costs for all Concomitant medications were s94 [95%CI s79–s109] andfor hospital admissions s120 [s74–s166] per mebeverine user. In mebeverine users with Concomitant laxative use thesecosts were s136 and s251 respectively.Conclusions In treated IBS patients, Concomitant Drug use and hospitalizations are increased relative to matched controls.Medical resource use and associated health care costs are particularly increased in mebeverine users using laxatives. Thetotal mean excess cost per patient per year is s482. Copyright # 2004 John Wiley & Sons, Ltd.key words—mebeverine; irritable bowel syndrome; matched case control study; incidence; laxatives; hospital morbidity;co-medication; health care costs